| A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours (NCT07533708) | Shanghai Henlius Biotech | 2026-07-30 |
| A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors (NCT07518043) | Shanghai Henlius Biotech | 2026-07-15 |
| A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer (NCT07601620) | Shanghai Henlius Biotech | 2026-07-03 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors (NCT07473726) | Shanghai Henlius Biotech | 2026-06-30 |
| A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer (NCT07543471) | Shanghai Henlius Biotech | 2026-06-30 |
| A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NCT07459751) | Shanghai Henlius Biotech | 2026-05-27 |
| A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NCT07477587) | Shanghai Henlius Biotech | 2026-05-27 |
| A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors (NCT07541534) | Shanghai Henlius Biotech | 2026-05-22 |
| A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects (NCT07484893) | Shanghai Henlius Biotech | 2026-05-14 |
| Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo® (NCT07495930) | Shanghai Henlius Biotech | 2026-04-30 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (NCT07416695) | Shanghai Henlius Biotech | 2026-04-17 |
| A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer (NCT07459738) | Shanghai Henlius Biotech | 2026-04-01 |
| Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor (NCT07480681) | Shanghai Henlius Biotech | 2026-03-01 |
| A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer (NCT07318883) | Shanghai Henlius Biotech | 2026-03-01 |
| A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (NCT07294508) | Shanghai Henlius Biotech | 2026-02-27 |
| A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer (NCT07253142) | Shanghai Henlius Biotech | 2026-02-05 |
| A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer (NCT07358585) | Shanghai Henlius Biotech | 2026-01-31 |
| A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer (NCT07294534) | Shanghai Henlius Biotech | 2026-01-27 |
| A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC (NCT07269782) | Shanghai Henlius Biotech | 2026-01-20 |
| A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (NCT07274813) | Shanghai Henlius Biotech | 2025-12-29 |
| A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors (NCT07160335) | Shanghai Henlius Biotech | 2025-09-26 |
| Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer (NCT07106892) | Shanghai Henlius Biotech | 2025-09-15 |
| Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07115485) | Shanghai Henlius Biotech | 2025-09-15 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis (NCT07038382) | Shanghai Henlius Biotech | 2025-08-05 |
| A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC (NCT06812260) | Shanghai Henlius Biotech | 2025-06-24 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT06907615) | Shanghai Henlius Biotech | 2025-06-09 |
| Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics (NCT06980454) | Shanghai Henlius Biotech | 2025-06-04 |
| A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma (NCT06841185) | Shanghai Henlius Biotech | 2025-04-30 |
| A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (NCT06847334) | Shanghai Henlius Biotech | 2025-04-27 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06857279) | Shanghai Henlius Biotech | 2025-04-22 |
| A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients (NCT06832202) | Shanghai Henlius Biotech | 2025-04-16 |
| A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy (NCT06839066) | Shanghai Henlius Biotech | 2025-04-02 |
| A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NCT06895512) | Shanghai Henlius Biotech | 2025-04-01 |
| A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy (NCT06742892) | Shanghai Henlius Biotech | 2025-03-03 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors (NCT06769152) | Shanghai Henlius Biotech | 2025-02-20 |
| A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy (NCT06769113) | Shanghai Henlius Biotech | 2025-01-26 |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer (NCT06532006) | Shanghai Henlius Biotech | 2024-11-22 |
| A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (NCT06349980) | Shanghai Henlius Biotech | 2024-08-05 |
| Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma (NCT05788107) | Shanghai Henlius Biotech | 2024-06-01 |
| A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects (NCT06310746) | Shanghai Henlius Biotech | 2024-04-23 |
| A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects (NCT06309043) | Shanghai Henlius Biotech | 2024-04-22 |
| A Study of HLX42 in Advanced/Metastatic Solid Tumors (NCT06210815) | Shanghai Henlius Biotech | 2024-03-14 |
| A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects (NCT06159101) | Shanghai Henlius Biotech | 2023-11-28 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (NCT05787613) | Shanghai Henlius Biotech | 2023-07-10 |
| Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects (NCT05902728) | Shanghai Henlius Biotech | 2023-07-04 |
| Mass Balance Study of [14C]HLX208 in China Healthy Subjects (NCT05841940) | Shanghai Henlius Biotech | 2023-06-17 |
| Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC (NCT05584137) | Shanghai Henlius Biotech | 2023-06-15 |
| HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors (NCT05360368) | Shanghai Henlius Biotech | 2023-03-30 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer (NCT05354700) | Shanghai Henlius Biotech | 2023-03-29 |
| A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation (NCT05641493) | Shanghai Henlius Biotech | 2023-02-28 |
| A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects (NCT05679258) | Shanghai Henlius Biotech | 2023-01-31 |
| Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients (NCT05675748) | Shanghai Henlius Biotech | 2023-01-15 |
| Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China (NCT05682599) | Shanghai Henlius Biotech | 2023-01-06 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors (NCT05442996) | Shanghai Henlius Biotech | 2023-01-06 |
| A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors (NCT05483530) | Shanghai Henlius Biotech | 2022-12-14 |
| A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (NCT05394168) | Shanghai Henlius Biotech | 2022-12-09 |
| A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma (NCT05606380) | Shanghai Henlius Biotech | 2022-12-02 |
| To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC (NCT05468489) | Shanghai Henlius Biotech | 2022-11-18 |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC (NCT04465734) | Shanghai Henlius Biotech | 2022-11-15 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation (NCT05528406) | Shanghai Henlius Biotech | 2022-10-20 |
| A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer (NCT04806945) | Shanghai Henlius Biotech | 2022-09-30 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC (NCT05221658) | Shanghai Henlius Biotech | 2022-08-25 |
| HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma (NCT05290220) | Shanghai Henlius Biotech | 2022-08-01 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (NCT05400265) | Shanghai Henlius Biotech | 2022-07-26 |
| A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (NCT04797468) | Shanghai Henlius Biotech | 2022-07-18 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC (NCT05239650) | Shanghai Henlius Biotech | 2022-07-15 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (NCT05390528) | Shanghai Henlius Biotech | 2022-06-20 |
| The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) (NCT05238363) | Shanghai Henlius Biotech | 2022-06-15 |
| HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors (NCT05360381) | Shanghai Henlius Biotech | 2022-06-03 |
| A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer (NCT05353257) | Shanghai Henlius Biotech | 2022-05-17 |
| HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05102214) | Shanghai Henlius Biotech | 2022-05-03 |
| A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer (NCT05346224) | Shanghai Henlius Biotech | 2022-04-25 |
| HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer (NCT05246982) | Shanghai Henlius Biotech | 2022-03-23 |
| The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation (NCT05127759) | Shanghai Henlius Biotech | 2022-03-23 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation (NCT05114603) | Shanghai Henlius Biotech | 2022-03-21 |
| A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC (NCT04976647) | Shanghai Henlius Biotech | 2022-01-18 |
| HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors (NCT04965220) | Shanghai Henlius Biotech | 2022-01-05 |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment (NCT05092802) | Shanghai Henlius Biotech | 2021-12-23 |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation (NCT05102292) | Shanghai Henlius Biotech | 2021-12-10 |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation (NCT05092815) | Shanghai Henlius Biotech | 2021-12-06 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation (NCT05065398) | Shanghai Henlius Biotech | 2021-11-15 |
| Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD (NCT05003245) | Shanghai Henlius Biotech | 2021-11-01 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma (NCT05078593) | Shanghai Henlius Biotech | 2021-10-11 |
| Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer (NCT04908813) | Shanghai Henlius Biotech | 2021-09-29 |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment (NCT04984369) | Shanghai Henlius Biotech | 2021-08-11 |
| Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD (NCT04993352) | Shanghai Henlius Biotech | 2021-07-15 |
| A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD (NCT04740671) | Shanghai Henlius Biotech | 2021-07-01 |
| A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) (NCT04547166) | Shanghai Henlius Biotech | 2021-03-10 |
| A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects (NCT04670796) | Shanghai Henlius Biotech | 2021-03-02 |
| Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers (NCT05429385) | Shanghai Henlius Biotech | 2020-12-09 |
| Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects (NCT04534582) | Shanghai Henlius Biotech | 2020-11-03 |
| Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. (NCT04671420) | Shanghai Henlius Biotech | 2020-10-01 |
| Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors (NCT04297995) | Shanghai Henlius Biotech | 2020-07-29 |
| Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects (NCT04411550) | Shanghai Henlius Biotech | 2020-07-01 |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) (NCT04301739) | Shanghai Henlius Biotech | 2020-04-17 |
| A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy (NCT04150575) | Shanghai Henlius Biotech | 2020-03-10 |
| A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer (NCT04139135) | Shanghai Henlius Biotech | 2019-12-12 |
| A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03952403) | Shanghai Henlius Biotech | 2019-12-02 |
| A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients (NCT03973112) | Shanghai Henlius Biotech | 2019-09-24 |
| A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC (NCT04063163) | Shanghai Henlius Biotech | 2019-09-12 |